1. Norway Stocks

  2. •

    Consumer non-durables

  3. •

    Food: specialty/candy
Hofseth Biocare ASA

Hofseth Biocare ASA

0.11
EUR
0.00
(0.00%)
-0.03EPS
59.23MMarket Cap
Hofseth Biocare ASA
GETTEX:HBQ
(Gettex)

Recent

price

0.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
NOK
0.01
0.03
0.45
0.87
0.22
0.52
0.14
0.51
0.23
0.22
0.21
0.24
0.32
0.49
0.63
0.62
0.59
Revenue per Share
-0.33
-0.45
-1.29
-0.72
-0.73
-0.95
-1.01
-0.07
-0.33
-0.29
-0.31
-0.35
-0.37
-0.27
-0.3
-0.33
-0.33
Basic EPS, GAAP
-1.29
-1.15
-1.14
-1.46
-0.78
-0.04
-0.75
-0.17
-0.15
-0.17
-0.35
-0.28
-0.17
-0.03
-0.04
-0.12
-0.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.57
2.1
0.84
0.8
0.81
0.3
0.23
0.16
0.29
0.36
0.74
0.39
0.38
0.11
0.15
-0.19
-0.06
Book Value per Share
0.99
1.42
0.16
0.48
0.55
0.09
0.16
0.09
0.23
0.29
0.62
0.25
0.22
-0.03
0.04
-0.28
-0.13
Tangible Book Value per Share
28
43
57
73
91
106
146
234
259
307
334
358
375
395
411
411
411
Basic Weighted Avg Shares
- -
1
26
63
20
55
20
118
61
68
69
88
120
195
257
256
242
Sales/Revenue/Turnover
-7,546.78
-2,055.62
-223.12
-77.77
-325.82
-171.51
-719.93
-10.11
-129.2
-118.55
-133.18
-135.32
-106.78
-64.74
-43.98
-43.79
-47.27
Operating Margin (%)
- -
2
8
13
18
19
26
22
22
27
27
29
30
36
40
39
41
Depreciation Expense
-9
-19
-74
-52
-67
-100
-147
-16
-85
-89
-102
-126
-137
-107
-125
-135
-137
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-5,489.47
-1,609.13
-283.91
-82.84
-338.5
-181.72
-729.81
-13.91
-139.56
-131.62
-147.42
-144.34
-114.06
-54.75
-48.68
-52.62
-56.38
Profit Margin (%)
- -
25
-64
-16
14
13
-23
-8
29
66
165
19
4
-121
-56
-79
-37
Working Capital
3
22
- -
36
45
86
46
44
30
104
89
125
91
97
112
229
217
LT Debt
76
121
48
62
79
33
54
37
86
118
264
140
148
41
59
-76
-31
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-19.38
-87.53
-94
-94.11
-177.67
-337.36
-35.83
-136.21
-86.97
-53.33
-62.37
-94.82
-111.98
-245.99
- -
- -
Return on Common Equity (%)

Capital Structure

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
131
134
121
LT Borrowings
139
219
217
LT Finance Leases
90
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
395
395
506
Market Capitalization
475
565
669

Working Capital

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
162
136
204
Cash, Cash Equivalents & STI
63
49
108
Accounts Receivable, Net
22
20
30
Inventories
60
60
54
Total Current Liabilities
241
261
241
Payables & Accruals
- -
- -
- -
ST Debt
131
134
121
Deferred Revenue
- -
- -
- -

Growth Rates

NOK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.02%
-59.3%
-227.26%
Free Cash Flow
294.71%
23.17%
211.98%
Net Income, GAAP
42.78%
7.05%
7.65%
Sales/Revenue/Turnover
54.55%
31.49%
-0.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
52
72
68
65
257
2025
61
68
55
72
256
2026
49
66
- -
- -
- -

Quarterly Earnings Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.07
-0.04
-0.09
-0.11
-0.3
2025
-0.08
-0.06
-0.07
-0.12
-0.33
2026
-0.09
-0.06
- -
- -
- -

Quarterly Dividends Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PepsiCo, Inc. (NASDAQ:PEP)
Britannia Industries Ltd (NSE:BRITANNIA)
Tata Consumer Products Limited (NSE:TATACONSUM)
Ulker Biskuvi Sanayi A.S. (BIST:ULKER)
Mondelez International, Inc. (NASDAQ:MDLZ)
The Hershey Company (NYSE:HSY)
Business
Hofseth BioCare ASA is a Norway-based biotech company specializing in the production and sale of high-value health nutritional products for humans and pets, focusing primarily on ingredients derived from fresh salmon by-products. The company's main products include ProGo®, a blend of bioactive peptides and collagen; OmeGo®, a full-spectrum salmon oil containing all fish fatty acid fractions; and CalGo®/NT-II®, salmon bone powder rich in hydroxyapatite and denatured collagen aimed at promoting bone and joint health. Hofseth BioCare operates a fully integrated salmon processing business that transforms fresh salmon off-cuts into sustainable nutritional ingredients and finished products marketed in Norway, the United Kingdom, France, Belgium, Italy, Germany, and other international locations. The company targets human health and premium pet nutrition markets and emphasizes sustainability, traceability, and the optimal utilization of marine resources. Founded in 1994 and headquartered in Ålesund, Norway, Hofseth BioCare has expanded its global footprint with offices in Oslo, London, Zürich, New Jersey, and Palo Alto. Recent major developments include a strategic partnership with Symrise to enhance market access and scale, the establishment of a second hydrolysis plant in Berkåk through its subsidiary HBC Berkåk AS to increase production capacity, and the spin-out of HBC Immunology (HBCI), a biotech-focused company working on pharmaceutical drug leads in oncology and asthma with external financing. In 2024-2025, Hofseth BioCare saw strong revenue growth driven by its B2B human nutrition product lines, especially ProGo®, OmeGo®, and CalGo®, which have received scientific validation and awards such as the NutraIngredients-USA “Healthy Aging” Award. The Midsund facility achieved record processing volumes, and the company launched new products like the collagen ingredient NT-II™ and extended its consumer and pet health product lines on European retail platforms including Amazon.de. Ongoing clinical studies reinforce the health benefits of its ingredients, supporting claims related to immune health, respiratory function, bone mass, and energy metabolism. These initiatives underscore the company's commitment to innovation, sustainability, and expanding its position in the science-led marine nutrition segment.